BRPI9917760B8 - método para isolar uma forma tetramérica de uricase a partir de uma solução de uricase purificada - Google Patents
método para isolar uma forma tetramérica de uricase a partir de uma solução de uricase purificadaInfo
- Publication number
- BRPI9917760B8 BRPI9917760B8 BRPI9917760A BR9917760A BRPI9917760B8 BR PI9917760 B8 BRPI9917760 B8 BR PI9917760B8 BR PI9917760 A BRPI9917760 A BR PI9917760A BR 9917760 A BR9917760 A BR 9917760A BR PI9917760 B8 BRPI9917760 B8 BR PI9917760B8
- Authority
- BR
- Brazil
- Prior art keywords
- uricase
- isolating
- purified
- solution
- tetrameric form
- Prior art date
Links
- 108010092464 Urate Oxidase Proteins 0.000 title abstract 4
- 230000002163 immunogen Effects 0.000 abstract 2
- -1 poly(ethylene glycols) Polymers 0.000 abstract 2
- 238000007385 chemical modification Methods 0.000 abstract 1
- 230000021615 conjugation Effects 0.000 abstract 1
- 230000009145 protein modification Effects 0.000 abstract 1
- 229940005267 urate oxidase Drugs 0.000 abstract 1
- 230000001751 uricolytic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
- C12N9/0044—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on other nitrogen compounds as donors (1.7)
- C12N9/0046—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on other nitrogen compounds as donors (1.7) with oxygen as acceptor (1.7.3)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N11/00—Carrier-bound or immobilised enzymes; Carrier-bound or immobilised microbial cells; Preparation thereof
- C12N11/02—Enzymes or microbial cells immobilised on or in an organic carrier
- C12N11/08—Enzymes or microbial cells immobilised on or in an organic carrier the carrier being a synthetic polymer
- C12N11/089—Enzymes or microbial cells immobilised on or in an organic carrier the carrier being a synthetic polymer obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicinal Preparation (AREA)
- Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13039298A | 1998-08-06 | 1998-08-06 | |
| US09/130,132 | 1998-08-06 | ||
| PCT/US1999/017514 WO2000007629A2 (en) | 1998-08-06 | 1999-08-02 | Peg-urate oxidase conjugates and use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BR9917760B1 BR9917760B1 (pt) | 2014-11-25 |
| BRPI9917760B8 true BRPI9917760B8 (pt) | 2021-05-25 |
Family
ID=22444494
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI9917760A BRPI9917760B8 (pt) | 1998-08-06 | 1999-08-02 | método para isolar uma forma tetramérica de uricase a partir de uma solução de uricase purificada |
| BRPI9912974A BRPI9912974B8 (pt) | 1998-08-06 | 1999-08-02 | conjugados de peg-urato oxidase e seu uso |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI9912974A BRPI9912974B8 (pt) | 1998-08-06 | 1999-08-02 | conjugados de peg-urato oxidase e seu uso |
Country Status (13)
| Country | Link |
|---|---|
| EP (1) | EP1100542B1 (show.php) |
| JP (3) | JP5183836B2 (show.php) |
| KR (2) | KR100614212B1 (show.php) |
| AU (1) | AU770014B2 (show.php) |
| BR (2) | BRPI9917760B8 (show.php) |
| CZ (1) | CZ303751B6 (show.php) |
| HU (2) | HU228916B1 (show.php) |
| IL (3) | IL141220A0 (show.php) |
| NZ (1) | NZ509595A (show.php) |
| PL (2) | PL202799B1 (show.php) |
| RU (3) | RU2278680C2 (show.php) |
| TW (1) | TW570981B (show.php) |
| WO (1) | WO2000007629A2 (show.php) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2290439C2 (ru) | 1998-08-06 | 2006-12-27 | Дьюк Юниверсити | Рекомбинантный белок уриказы млекопитающего для конъюгирования с пэг, молекула нуклеиновой кислоты, кодирующая его, вектор для его экспрессии, способ его получения и применение |
| PL202799B1 (pl) * | 1998-08-06 | 2009-07-31 | Mountain View Pharmaceuticals | Sposób izolowania urykazy w postaci tetramerycznej oraz wyizolowana tetrameryczna urykaza |
| EP2316475B1 (en) | 1998-08-06 | 2017-10-04 | Mountain View Pharmaceuticals, Inc. | Isolated tetrameric uricase |
| US6783965B1 (en) | 2000-02-10 | 2004-08-31 | Mountain View Pharmaceuticals, Inc. | Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates |
| AU2006203252B8 (en) * | 2000-02-10 | 2009-06-18 | Duke University | Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates |
| WO2001074400A1 (en) | 2000-04-03 | 2001-10-11 | Santen Pharmaceutical Co., Ltd. | Transporters and drug delivery system by using the same |
| EP1317258B1 (en) | 2000-06-28 | 2009-02-11 | Merck & Co., Inc. | Use of allopurinol for the treatment of hypertension |
| AU2002345938A1 (en) | 2001-06-28 | 2003-03-03 | Mountain View Pharmaceuticals, Inc. | Polymer stabilized proteinases |
| US6913915B2 (en) * | 2001-08-02 | 2005-07-05 | Phoenix Pharmacologics, Inc. | PEG-modified uricase |
| US20040062748A1 (en) | 2002-09-30 | 2004-04-01 | Mountain View Pharmaceuticals, Inc. | Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof |
| US8129330B2 (en) | 2002-09-30 | 2012-03-06 | Mountain View Pharmaceuticals, Inc. | Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof |
| US7919118B2 (en) | 2003-05-12 | 2011-04-05 | Affymax, Inc. | Spacer moiety for poly (ethylene glycol) modified peptide based compounds |
| KR101227666B1 (ko) | 2003-05-12 | 2013-01-31 | 아피맥스, 인크. | 에리스로포이에틴 수용체에 결합하는 펩티드 |
| KR101146160B1 (ko) * | 2004-06-30 | 2012-07-16 | 넥타르 테라퓨틱스 | 중합체인자 ｉｘ 부분의 접합체 |
| US8148123B2 (en) | 2005-04-11 | 2012-04-03 | Savient Pharmaceuticals, Inc. | Methods for lowering elevated uric acid levels using intravenous injections of PEG-uricase |
| TW200716751A (en) | 2005-04-11 | 2007-05-01 | Savient Pharmaceuticals Inc | A variant form of urate oxidase and use thereof |
| PL3321359T3 (pl) | 2005-04-11 | 2021-06-28 | Horizon Pharma Rheumatology Llc | Wariantowe postacie oksydazy moczanowej i ich zastosowanie |
| EP1883405A4 (en) | 2005-05-09 | 2010-01-27 | Takeda Pharmaceuticals North A | METHODS OF TREATING NEPHROLITHIASIS |
| US7550433B2 (en) | 2005-06-03 | 2009-06-23 | Affymax, Inc. | Erythropoietin receptor peptide formulations and uses |
| EP2013225B1 (en) | 2006-04-12 | 2014-12-17 | Crealta Pharmaceuticals LLC | Purification of proteins with cationic surfactant |
| JP4890132B2 (ja) * | 2006-07-20 | 2012-03-07 | 東洋紡績株式会社 | ウリカーゼの比活性を向上させる方法、および比活性の向上した改変型ウリカーゼ |
| RU2382048C1 (ru) * | 2008-12-25 | 2010-02-20 | Общество С Ограниченной Ответственностью "Фармапарк" | Лекарственное средство на основе модифицированного интерферона альфа с пролонгированным терапевтическим действием |
| PL398781A1 (pl) | 2009-06-25 | 2012-11-19 | Savient Pharmaceuticals, Inc. | Sposoby i zestawy do prognozowania ryzyka wystapienia reakcji na wlew oraz zaniku odpowiedzi której posrednicza przeciwciala poprzez monitorowanie kwasu moczowego w surowicy podczas terapii z zastosowaniem pegylowanej urykazy |
| EP2613780B1 (en) | 2010-09-10 | 2014-11-12 | Takeda Pharmaceuticals U.S.A., Inc. | Methods for concomitant treatment of theophylline and febuxostat |
| CN102634492B (zh) | 2011-02-14 | 2015-06-10 | 重庆富进生物医药有限公司 | 聚乙二醇化犬源尿酸氧化酶类似物及其制备方法和应用 |
| CA2869557A1 (en) | 2012-04-06 | 2013-10-10 | Indus Pharmaceuticals, Inc. | Novel compositions of combinations of non-covalent dna binding agents and anti-cancer and/or anti-inflammatory agents and their use in disease treatment |
| BR112015027279A8 (pt) | 2013-05-03 | 2018-01-30 | Selecta Biosciences Inc | métodos e composições para acentuar células t reguladoras cd4+ |
| EP3294322A4 (en) | 2015-05-15 | 2018-12-12 | Medimmune, LLC | Improved uricase sequences and methods of treatment |
| CN105412942B (zh) * | 2015-12-23 | 2019-02-26 | 沈阳三生制药有限责任公司 | 聚乙二醇化的重组产朊假丝酵母尿酸氧化酶冻干注射剂 |
| US20200237881A1 (en) | 2019-01-30 | 2020-07-30 | Horizon Pharma Rheumatology Llc | Reducing immunogenicity to pegloticase |
| EP3538135A4 (en) | 2016-11-11 | 2020-07-29 | Horizon Pharma Rheumatology LLC | POLYTHERAPIES OF PREDNISONE AND URICASE MOLECULES AND THEIR USES |
| EP3592389B1 (en) | 2017-03-11 | 2025-05-07 | Cartesian Therapeutics, Inc. | Methods and compositions related to combined treatment with anti-inflammatories and synthetic nanocarriers comprising an immunosuppressant |
| CN112980808B (zh) * | 2019-12-12 | 2024-10-29 | 深圳迈瑞生物医疗电子股份有限公司 | 尿酸酶、及其制备方法和用途 |
| MX2023005235A (es) | 2020-11-03 | 2023-10-16 | Protalix Ltd | Uricasa modificada y usos de la misma. |
| CN114438048B (zh) * | 2020-11-05 | 2024-10-22 | 重庆派金生物科技有限公司 | 尿酸氧化酶制剂及其应用 |
| CN114438047B (zh) * | 2020-11-05 | 2024-11-22 | 重庆派金生物科技有限公司 | 制备聚乙二醇修饰的尿酸氧化酶的方法 |
| US20240060063A1 (en) | 2021-02-10 | 2024-02-22 | Oriental Yeast Co., Ltd. | Uricase activator and uric acid measurement reagent |
| CN114181917B (zh) * | 2022-02-14 | 2022-06-03 | 潍坊华卓生物科技有限公司 | 一种改造尿酸酶、基因序列、制备方法及应用 |
| US12269875B2 (en) | 2023-08-03 | 2025-04-08 | Jeff R. Peterson | Gout flare prevention methods using IL-1BETA blockers |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR6301M (show.php) * | 1967-03-29 | 1968-09-09 | ||
| US3616231A (en) * | 1968-11-14 | 1971-10-26 | Boehringer Mannheim Gmbh | Process for the production of uricase |
| US4179337A (en) * | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| JPS6031472B2 (ja) * | 1978-12-14 | 1985-07-22 | 協和醗酵工業株式会社 | 酸性ウリカ−ゼ |
| JPS55135590A (en) * | 1979-04-05 | 1980-10-22 | Mihama Hisaharu | Modified asparaginase and uricase and their preparation |
| JPS57192435A (en) * | 1981-05-20 | 1982-11-26 | Toyobo Co Ltd | Modified polypeptide |
| JPS6255079A (ja) * | 1986-04-23 | 1987-03-10 | Mihama Hisaharu | 修飾ウリカ−ゼ |
| NZ234453A (en) * | 1989-07-13 | 1993-01-27 | Sanofi Sa | Recombinant dna encoding urate oxidase, and vector, host, protein and pharmaceutical compositions associated therewith |
| US6783965B1 (en) * | 2000-02-10 | 2004-08-31 | Mountain View Pharmaceuticals, Inc. | Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates |
| RU2290439C2 (ru) * | 1998-08-06 | 2006-12-27 | Дьюк Юниверсити | Рекомбинантный белок уриказы млекопитающего для конъюгирования с пэг, молекула нуклеиновой кислоты, кодирующая его, вектор для его экспрессии, способ его получения и применение |
| PL202799B1 (pl) * | 1998-08-06 | 2009-07-31 | Mountain View Pharmaceuticals | Sposób izolowania urykazy w postaci tetramerycznej oraz wyizolowana tetrameryczna urykaza |
-
1999
- 1999-08-02 PL PL380583A patent/PL202799B1/pl unknown
- 1999-08-02 BR BRPI9917760A patent/BRPI9917760B8/pt not_active IP Right Cessation
- 1999-08-02 IL IL14122099A patent/IL141220A0/xx active IP Right Grant
- 1999-08-02 NZ NZ509595A patent/NZ509595A/xx not_active IP Right Cessation
- 1999-08-02 AU AU52515/99A patent/AU770014B2/en not_active Ceased
- 1999-08-02 BR BRPI9912974A patent/BRPI9912974B8/pt not_active IP Right Cessation
- 1999-08-02 HU HU0800112A patent/HU228916B1/hu not_active IP Right Cessation
- 1999-08-02 KR KR1020047014428A patent/KR100614212B1/ko not_active Expired - Fee Related
- 1999-08-02 JP JP2000563311A patent/JP5183836B2/ja not_active Expired - Fee Related
- 1999-08-02 PL PL383331A patent/PL220873B1/pl unknown
- 1999-08-02 CZ CZ20010317A patent/CZ303751B6/cs not_active IP Right Cessation
- 1999-08-02 WO PCT/US1999/017514 patent/WO2000007629A2/en not_active Ceased
- 1999-08-02 RU RU2004104953/15A patent/RU2278680C2/ru not_active IP Right Cessation
- 1999-08-02 HU HU0103003A patent/HU226294B1/hu not_active IP Right Cessation
- 1999-08-02 RU RU2001103144/15A patent/RU2246318C2/ru not_active IP Right Cessation
- 1999-08-02 KR KR10-2001-7001569A patent/KR100488848B1/ko not_active Expired - Fee Related
- 1999-08-02 EP EP99937745A patent/EP1100542B1/en not_active Expired - Lifetime
- 1999-08-05 TW TW088113406A patent/TW570981B/zh not_active IP Right Cessation
-
2001
- 2001-02-01 IL IL141220A patent/IL141220A/en not_active IP Right Cessation
-
2006
- 2006-03-09 RU RU2006107111/15A patent/RU2349341C2/ru not_active IP Right Cessation
-
2007
- 2007-06-14 IL IL183948A patent/IL183948A/en not_active IP Right Cessation
-
2009
- 2009-07-24 JP JP2009173148A patent/JP5290901B2/ja not_active Expired - Fee Related
-
2012
- 2012-11-12 JP JP2012248770A patent/JP5291235B2/ja not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI9917760B8 (pt) | método para isolar uma forma tetramérica de uricase a partir de uma solução de uricase purificada | |
| AU5624699A (en) | Use of 5ht-6 antagonists | |
| BR0108452A (pt) | Inibidores da oxidação parcial de ácido graxo no tratamento de insuficiência cardìaca congestiva | |
| WO2000008196A3 (en) | Urate oxidase | |
| BR0010428A (pt) | Uso de compostos | |
| IL183953A (en) | Method of reducing oxidant induced damage of a food product, a pharmaceutical or stored blood and novel compounds therefor | |
| BR9910251A (pt) | Estimulação hematopoiética | |
| NZ504258A (en) | Exendin 3 and 4 agonist compounds for the treatment of diabetes | |
| PT1112275E (pt) | Novos inibidores heteroaromaticos da frutose-1,6-bisfosfatase | |
| WO2003011211A3 (en) | Peg-modified uricase | |
| BR0211442A (pt) | Cepas de bifidobacterium probióticas | |
| SE9702860D0 (sv) | New use | |
| DE69943205D1 (de) | Peg-uricase Konjugate und Verwendung davon | |
| WO2002103103A3 (en) | Fluorine-containing compounds and polymers derived therefrom | |
| WO2001066553A3 (en) | Novel aryl fructose-1,6-bisphosphatase inhibitors | |
| BR0311161A (pt) | Método de tratamento de diabetes | |
| AU2002338852A1 (en) | Genes and proteins for prevention, prediction, prognosis and therapy of cardiovascular disease | |
| WO2002018361A3 (en) | Compounds having activity as inhibitors of cytochrome p450rai | |
| WO1999058098A8 (en) | HUMAN ANTITHROMBIN IIIs AND METHODS RELATED THERETO | |
| WO2002064816A3 (en) | Multiple determinants for metabolic phenotypes | |
| WO2004069781A3 (en) | 7-(3,5-diisopropylphenyl) heptatrienoic acid derivatives having serum glucose reducing activity | |
| WO2001007644A3 (en) | Genotyping of the paraoxonase 1 gene for prognosing, diagnosing, and treating a disease | |
| WO2003056897A3 (en) | Highly phosphorylated acid beta-glucocerebrosidase and methods of treating gaucher's disease | |
| BR0303367A (pt) | Células de mycobacterium w, veìculo farmaceuticamente aceitável, preservativo, ruptura de mycobacterium w, extração de solvente, enzimas usadas para a extração enzimática de células de mycobacterium w, adjuvante, composição farmacêutica, tensoativo, e, concentração de tensoativo do processo de fabricar uma composição farmacêutica para a administração de tuberculose | |
| BR0213478A (pt) | Processo de produção de heparina, e, preparação de heparina |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B24H | Lapse because of non-payment of annual fees (definitively: art 78 iv lpi) |
Free format text: EXTINCAO DEFINITIVA - ART. 78 INCISO IV DA LPI |
|
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 25/11/2014, OBSERVADAS AS CONDICOES LEGAIS. |
|
| B24E | Patent annual fee: resolution cancelled |
Free format text: REFERENTE AO DESPACHO 24.8 PUBLICADO NA RPI 2289 DE 18/11/2014. |
|
| B15K | Others concerning applications: alteration of classification |
Ipc: C12N 9/06 (2006.01), A61K 47/60 (2017.0 |
|
| B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 02/08/1999 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |
|
| B21A | Patent or certificate of addition expired [chapter 21.1 patent gazette] |
Free format text: PATENTE EXTINTA EM 02/08/2019 |